Search the database for deliberate release of GM medicinal products
Displaying 1 - 3 of 3
| EU record number | Title | Company / Sponsor | Treated organism | Genetic modification |
|---|---|---|---|---|
| CP0201-NHL | A Phase I/II, multicenter study, evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodglin lymphoma | CellPoint B.V. | Humans | CD19-CAR |
| B/BE/07/BVW1 | Phase 1b and Phase 2a clinical trials with an hIL-10-expressing Lactococcus lactis | ActoGeniX N.V. | Humans | Gene coding for the human interleukin-10 (hIL-10) |
| Only notified under the "contained use" procedure. Dossier submitted on . | A phase III, multi-center, open-label, randomized study to compare the overall survival and safety of bi-weekly intratumoral administration of INGN 201 versus weekly methotrewate in 240 patients with refractory squamous cell carcinoma of the head and neck | Introgen Therapeutics, Inc. | Humans | Wild-type p53 |